類器官Dexamethasone (DHAP)

類器官（Organoids）是指將成體干細胞或多能干細胞在體外三維培養(yǎng)形成的具有一定空間結構的組織類似物。類器官在組織結構、細胞類型、自我更新能力和功能等方面與來源組織高度一致，從而在發(fā)育生物學、疾病造模、精準醫(yī)學、藥物研發(fā)、基因和細胞療法、感染和免疫以及再生醫(yī)學等生物醫(yī)學的多個領域展現(xiàn)出*的優(yōu)勢。

產(chǎn)品介紹DESCRIPTION

技術參數(shù)BIOLOGICAL ALTIVITY
In Vitro   
Dexamethasone regulates several transcription factors, including activator protein-1, nuclear factor-AT, and nuclear factor-kB, leading to the activation and repression of key genes involved in the inflammatory response^[1].
Dexamethasone potently inhibits granulocyte-macrophage colony stimulating factor (GM-CSF) release from A549 cells with EC50 of 2.2 nM. Dexamethasone (EC50=36 nM) induces transcription of the β2-receptor is found to correlate with glucocorticoid receptor (GR) DNA binding and occurred at 10-100 fold higher concentrations than the inhibition of GM-CSF release. Dexamethasone (IC50=0.5 nM) inhibits a 3×κB (NF-κB, IκBα, and I-κBβ), which is associated with inhibition of GM-CSF release^[2].
In Vivo  
It has previously been reported that treatment with Dexamethasone at a dose of 2×5 mg/kg efficiently inhibits lipopolysaccharide (LPS)-induced inflammation. In our experimental system, treatment with a single dose of Dexamethasone 10 mg/kg (i.p.) significantly decreases recruitment of granulocytes as well as spontaneous production of oxygen radicals compared with animals expose to LPS and injected with solvent alone (saline). The effects are statistically significant when administered both 1 h before and 1 h after inhalation of LPS. The number of granulocytes in BALF decreased to levels comparable to healthy animals (given an aerosol of water)^[3].

類器官Dexamethasone (DHAP)